Colorectal Cancer (CRC) Completed Phase 1 Trials for Pembrolizumab (DB09037)

Back to Colorectal Cancer (CRC)

Also known as: Malignant Neoplasm of Colorectum / CRC, Colorectal Cancer / Colorectal Cancer / Cancer, Colorectal / CRC (Colorectal Cancer) / Colorectal, Cancer / Colo-rectal Cancer / Colorectal Cancers / A. Colorectal Cancer / Cancer Colorectal / Gastrointestinal Cancers - Colorectal / CRC / CRCS / Malignant colorectal neoplasm / Malignant neoplasm of cecum and/or colon and/or rectum / Malignant neoplasm of caecum and/or colon and/or rectum / Malignant neoplasm of cecum and/or colon and/or rectum (disorder) / Malignant neoplasm of large intestine / Malignant tumor of large intestine / Malignant tumour of large intestine / Malignant neoplasm of large intestine (disorder) / Malignant neoplasm of colon, unspecified / Malignant large intestinal neoplasm NOS / Cancer of large intestine / Malignant neoplasm of large intestine, NOS / Cancer of large bowel / CA - Cancer of large bowel / Colorectal neoplasms malignant / Malignant neoplasm of colon and/or rectum (disorder) / Large intestine carcinoma / Colorectal carcinoma / Colorectal cancer NOS

Indication	Status	Phase
DBCOND0031867 (Colorectal Cancer (CRC))	Completed	1

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT03658772	Grapiprant and Pembrolizumab in Patients With Advanced or Progressive MSS Colorectal Cancer	Treatment	Grapiprant (DB12836) Pembrolizumab (DB09037)
NCT03095781	Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer	Treatment	Pembrolizumab (DB09037) XL-888 (DB12981)
NCT02713373	Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery	Treatment	Cetuximab (DB00002) Pembrolizumab (DB09037)
NCT02437136	Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC)	Treatment	Entinostat (DB11841) Pembrolizumab (DB09037)
NCT02178722	Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers	Treatment	Epacadostat (DB11717) Pembrolizumab (DB09037)
NCT04332653	NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors	Treatment	Efineptakin alfa (DB16395) Pembrolizumab (DB09037)
NCT05585034	Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors	Treatment	Pembrolizumab (DB09037) XmAb808 (DB23475)
NCT04344795	Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors	Treatment	Pembrolizumab (DB09037) TPST-1495 (DB22060)
NCT03761914	Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers	Treatment	Galinpepimut-S (DB17271) Pembrolizumab (DB09037) Sargramostim (DB00020)
NCT03454451	CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers	Treatment	Ciforadenant (DB16125) Mupadolimab (DB16488) Pembrolizumab (DB09037)
NCT03329950	A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies	Treatment	CDX-1140 (DB22517) CDX-301 (DB19293) Gemcitabine (DB00441) Paclitaxel (DB01229) Pembrolizumab (DB09037)
NCT02512172	A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer	Treatment	Azacitidine (DB00928) Pembrolizumab (DB09037) Romidepsin (DB06176)
NCT03841110	FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors	Treatment	Aldesleukin (DB00041) Atezolizumab (DB11595) Cyclophosphamide (DB00531) FT500 (DB30080) Fludarabine (DB01073) Nivolumab (DB09035) Pembrolizumab (DB09037)
NCT03332498	Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers	Treatment	Ibrutinib (DB09053) Pembrolizumab (DB09037)
NCT04256707	Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment	Treatment	Docetaxel (DB01248) Fluorouracil (DB00544) Irinotecan (DB00762) Leucovorin (DB00650) Pembrolizumab (DB09037) Selinexor (DB11942)
NCT02837263	PI Pembro in Combination With Stereotactic Body Radiotherapy for Liver Metastatic Colorectal Cancer	Treatment	Pembrolizumab (DB09037)
NCT02646748	Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors	Treatment	Itacitinib (DB12154) Parsaclisib (DB14867) Pembrolizumab (DB09037)
NCT02713529	Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer	Treatment	Amg-820 (DB33696) Pembrolizumab (DB09037)
NCT02903914	Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors	Treatment	Numidargistat (DB15286) Pembrolizumab (DB09037)
NCT05708950	A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)	Treatment	KVA12123 (DB27554) Pembrolizumab (DB09037)
NCT04354246	COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies	Treatment	COM701 (DB23082) COM902 (DB24398) Pembrolizumab (DB09037)